sutthirat sutthisumdang
Roth MKM started protection of Genelux (NASDAQ:GNLX) with a buy score, citing the corporate’s drug Olvi-Vec within the remedy of ovarian most cancers.
The funding agency stated that whereas it sees danger heading right into a pivotal readout in 2025, it believes regionally delivered Olvi-Vec is “positioned to succeed” in platinum resistant/refractory illness.
Roth additionally sees worth in systemically administered Olvi-Vec within the remedy of recurrent lung most cancers. It added that interim readouts anticipated in 2024 and mid-2025 “have a chance to succeed and reprice the stock.”
Roth set its value goal for the inventory at $10.
Source: Seekingalpha